Alliance HealthCare Services, Inc. (NASDAQ:AIQ) announced that it will host a conference call and webcast on Thursday, March 13, 2014 at 8:30 a.m. Eastern Time to discuss the Company’s fourth quarter and full year 2013 financial results and 2014 financial guidance. Alliance HealthCare Services, Inc. (NASDAQ:AIQ) shares after opening at $32.71 moved to $34.90 on last trade day and at the end of the day closed at $33.58. Company price to sales ratio in past twelve months was calculated as 0.80 and price to cash ratio as 10.32. Alliance HealthCare Services, Inc. (NASDAQ:AIQ) showed a positive weekly performance of 15.95%.
National HealthCare Corporation (NYSEMKT:NHC), one of the nation’s oldest publicly traded long-term health care providers and a leader of post-acute care services, announced the expansion of its Missouri operations. National HealthCare Corporation (NYSEMKT:NHC) shares advanced 0.51% in last trading session and ended the day on $55.58. NHC return on equity ratio is recorded as 10.80% and its return on assets is 5.70%. National HealthCare Corporation (NYSEMKT:NHC) yearly performance is 21.78%.
Johnson & Johnson’s (NYSE:JNJ) announced recently its subsidiary, Janssen Research & Development, will enter an agreement with Yale School of Medicine’s Open Data Access (YODA) Project, marking yet another valuable milestone in industry’s move towards responsible sharing of clinical trials data. Johnson & Johnson (NYSE:JNJ) shares moved down -0.34% in last trading session and was closed at $97.05 while trading in range of $97.05 – $98.47 – Johnson & Johnson (NYSE:JNJ) year to date (YTD) performance is 6.72%.
Retrophin (NASDAQ:RTRX) CEO Martin Shkreli bought 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average price of $18.44 per share, with a total value of $64,540.00. Retrophin Inc (NASDAQ:RTRX) weekly performance is 13.91%. On last trading day company shares ended up $20.56. Retrophin Inc (NASDAQ:RTRX) distance from 50-day simple moving average (SMA50) is 37.02%. Analysts mean target price for the company is $51.00.